Last Updated : January 27, 2014
Details
FilesGeneric Name:
Cetuximab
Project Status:
Complete
Therapeutic Area:
Metastatic Colorectal Cancer
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Erbitux
Project Line:
Reimbursement Review
Project Number:
PC0031-000
Strength:
2mg/ml, 100mg, 50ml single use vial
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
For the treatment of EGFR-expressing K-RAS wild Type metastatic colorectal carcinoma (mCRC) in combination with FOLFIRI (Irinotecan, 5-fluorouracil, leucovorin) for first line treatment
Review Status:
Complete
Sponsor:
pCODR Provincial Advisory Group
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Clarification:
Bristol-Myers Squibb Canada had requested a voluntary withdrawal of the Cetuximab (Erbitux) for mCRC Submission in anticipation of new clinical information and possible resubmission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has decided to continue the review as a PAG Submission in order to obtain a final recommendation that provinces can act on if needed.
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : January 27, 2014